Arbutus Biopharma CORP

Arbutus Biopharma announced receipt of $178M from Moderna settlement, initiated patent lawsuits against Pfizer/BioNTech, and plans to return up to $230M to shareholders.

Arbutus Biopharma Corporation shareholders approved the 2026 Omnibus Share and Incentive Plan at the Annual Meeting, replacing previous plans and authorizing 16.3 million common shares.

Arbutus Biopharma announced strong first quarter 2026 financial results, driven by a significant license revenue from the Genevant settlement with Moderna, alongside positive corporate updates including FDA Fast Track designation for imdusiran.

Arbutus Biopharma Corporation announced that the U.S. FDA has granted Fast Track designation for its investigational therapy, imdusiran, for the treatment of chronic hepatitis B.

Arbutus Biopharma announced a significant $2.25 billion global settlement with Moderna for LNP patent infringement, alongside its fourth quarter and full year 2025 financial results.

A U.S. District Court ruled that Arbutus's patent infringement claims against Moderna for most COVID-19 vaccine doses can proceed in district court, while limiting claims under the doctrine of equivalents.

Arbutus Biopharma reports a significant financial turnaround driven by a $950 million noncontingent settlement payment from Moderna, leading to a substantial net income and a strong cash position.

Arbutus Biopharma reported significantly reduced net losses in Q3 2025, driven by cost-cutting and deferred revenue, while advancing its cHBV clinical programs and patent litigation.

Arbutus Biopharma reported a significant revenue increase and a swing to net income in Q2 2025, driven by a terminated partnership and substantial cost reductions, while advancing its cHBV pipeline and patent litigation.

Arbutus Biopharma announces Q1 2025 financial results, details operational restructuring, and provides updates on ongoing patent infringement lawsuits against Moderna and Pfizer/BioNTech.

Arbutus Biopharma reported its Q3 2024 financial results, highlighting a strategic shift towards advancing its hepatitis B virus (HBV) pipeline and a restructuring to streamline operations.

Arbutus Biopharma announced its second quarter 2024 financial results and a strategic restructuring to focus on key clinical programs and extend its cash runway into the fourth quarter of 2026.

Arbutus Biopharma reports a significant patent settlement with Moderna for $950M noncontingent payment, while advancing its HBV pipeline and undergoing substantial corporate restructuring.

Arbutus Biopharma focuses on advancing its hepatitis B programs and LNP delivery technology while streamlining operations and reducing workforce.

Arbutus Biopharma's annual 10-K filing details its capital structure, ongoing clinical trials, and strategic focus on developing a functional cure for chronic hepatitis B.

Robert A. Beardsley, a Director at Arbutus Biopharma Corp, was granted 78,800 stock options.

Arbutus Biopharma's Chief Financial Officer, Tuan Nguyen, received grants of 73,500 restricted stock units and options to purchase 188,400 common shares.

Arbutus Biopharma's President and CEO, Lindsay Androski, received significant equity awards including restricted stock units and stock options.

Arbutus Biopharma Director Roger Sawhney was granted 157,600 stock options with an exercise price of $3.34, vesting over three years.

Tuan Nguyen, CFO of Arbutus Biopharma, was granted a stock option for 750,000 shares at an exercise price of $3.49, vesting over four years.

Tuan Nguyen, CFO of Arbutus Biopharma, was granted stock options for 750,000 common shares on March 31, 2025, vesting over four years.

Arbutus Biopharma Corporation has announced its 2026 Annual General and Special Meeting of Shareholders will be held on May 26, 2026, to elect directors, approve an incentive plan, and vote on executive compensation.

Arbutus Biopharma Corporation has filed a definitive proxy statement with the Securities and Exchange Commission.

Arbutus Biopharma will hold its 2025 Annual General Meeting of Shareholders virtually on May 21, 2025, to vote on director elections, executive compensation, and the appointment of an independent accounting firm.

Arbutus Biopharma Corporation has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Arbutus Biopharma is holding its 2024 Annual General and Special Meeting of Shareholders on May 22, 2024, to vote on director elections, an amendment to the 2016 Omnibus Share and Incentive Plan, executive compensation, and the appointment of an independent registered public accounting firm.

Whitefort Capital Master Fund has adjusted its position in Arbutus Biopharma, reaching an 8.0% beneficial ownership stake and 9.8% total economic exposure.

Whitefort Capital Master Fund, LP has significantly increased its holdings in Arbutus Biopharma Corp, acquiring over 15.7 million shares in the past 60 days.

Roivant Sciences Ltd., a significant shareholder in Arbutus Biopharma Corp, has successfully orchestrated a complete change in Arbutus's Board of Directors, reducing its size and appointing new leadership, including a new CEO.

Whitefort Capital Master Fund, LP has increased its beneficial ownership in Arbutus Biopharma Corp to 7.0% and plans to engage with the company and shareholders to drive value, including potential changes to the Board of Directors.

Roivant Sciences Ltd. has filed an Amendment No. 12 to its Schedule 13D, reaffirming its 20.5% beneficial ownership in Arbutus Biopharma Corp. and indicating potential near-term changes to the Issuer's board of directors and management.

Two Seas Capital LP and Sina Toussi have reported a 9.4% beneficial ownership stake in Arbutus Biopharma Corporation.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., reported beneficial ownership of 13.5% of Arbutus Biopharma Corp's common shares.

Two Seas Capital LP and its affiliates have disclosed a 5.4% beneficial ownership in Arbutus Biopharma Corporation as of June 30, 2025, held for investment purposes.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have filed an amended Schedule 13G, revealing a combined beneficial ownership of 11.4% in Arbutus Biopharma Corp as of December 31, 2024.